COMMITTED
TO EXCEPTIONAL ACCESS
*RINVOQ is on a preferred tier or otherwise has preferred status on the plan's formulary.
†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
What can PREFERRED COVERAGE mean for your RA, PsA, AS, and nr‑axSpA patients?
Accessibility
Covered after the trial of 1 TNFi ahead of non-preferred products.2,‡
‡Individual plan coverage/benefits may vary and are subject to change.
Affordability
Commercial:
- Lowest branded copay tier
Medicare Part D:
- Lowest coinsurance formulary tier§
§Copay assistance programs are not available to patients receiving prescription reimbursement under any federal, state or government-funded insurance programs (e.g., Medicare Part D and Medicare Advantage programs) or where prohibited by law or by the patient's health insurance provider.
How much do your patients pay?
Commercial
of commercial claims for a filled RINVOQ prescription cost patients $0–53,||
Your eligible, commercially insured patients may pay as little as $0 per month with the RINVOQ Complete Savings Card.¶,**
Medicare Part D
Low Income Subsidy
of RINVOQ rheumatology Medicare patients†† filled their prescription through the Medicare Part D Extra Help program, also known as the low-income subsidy (LIS)4
In 2026, patients with Medicare Part D Extra Help pay no more than $12.65 per covered branded prescription.5
Medicare Part D Benefit
In 2026, annual out-of-pocket costs will be capped at $2,100 for people with Medicare Part D.
Patients can opt into the Medicare Prescription Payment Plan (MPPP) through their Part D plan to spread their out-of-pocket costs over the year.
Patients who start taking RINVOQ in 2026 can contact their Part D plan for an estimated monthly payment.6
||Based upon paid commercial claims data from national data providers for a filled RINVOQ prescription for RA, PsA, and AS for the period February 2024-January 2025, inclusive of savings card redemptions.3
¶Patients’ actual out-of-pocket cost may vary depending on their insurance coverage and eligibility for support programs.
**RINVOQ Complete Savings Card Terms and Conditions Eligibility: Available to patients with commercial insurance coverage for RINVOQ who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit RINVOQSavingsCard.com or call 1.800.2RINVOQ for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy.
††65% of RINVOQ rheumatology patients are estimated to be enrolled in LIS. Based on Medicare Part D rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis claims data from July 2023 through June 2024.4
Check the Formulary Status for RINVOQ in Your Area
Formulary Zipcode
Choose Indication
Formulary Status Results
- Plan Name
- Plan Type
- Status
Results ends here
- Plan Name
- Plan Type
- Status
Results ends here
Preferred means RINVOQ is on a preferred tier or otherwise has preferred status on the plan’s formulary.
AS=active ankylosing spondylitis*; IR=inadequate response; nr-axSpA=active non-radiographic axial spondyloarthritis†; PsA=active psoriatic arthritis*; RA=moderate to severe rheumatoid arthritis*; TNFi=tumor necrosis factor inhibitor.
*In adult TNFi-IR patients
†In adult TNFi-IR patients with objective signs of inflammation.
